Még nem toboroz
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· 2. fázis· Agomab Spain S.L.U.· Forrás
Még nem toboroz
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:”
“A multi-arms prospective, randomized phase II study to evaluate the best sequential
therapeutic strategis in patients with metastatic non-small cell lung cancer harboring
targetable genomic driver alterations”
2026-525268-16-00· 2/3. fázis· Universita' Degli Studi Di Torino· Forrás
Toboroz
A study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL
2025-524915-36-00· 1/2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· AstraZeneca· Forrás
Toboroz
Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed after, CAR T-cell therapy.
2025-523428-39-00· 2. fázis· Fondazione Italiana Linfomi Ets· Forrás
Toboroz
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· 3. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Toboroz
A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.
2025-521074-34-00· 2. fázis· Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare· Forrás
Toboroz
ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
NCT07381764· 2. fázis· Gruppo Oncologico Italia Meridionale· Forrás
Toboroz
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás
Toboroz
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· 3. fázis· Syndax Pharmaceuticals· Forrás
Toboroz
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás
Toboroz
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312· 3. fázis· Kura Oncology, Inc.· Forrás
Toboroz
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· 1/2. fázis· BioNTech SE· Forrás
Toboroz
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· 3. fázis· AstraZeneca· Forrás
Toboroz
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502· 3. fázis· Celgene· Forrás
Toboroz
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· 2/3. fázis· Eikon Therapeutics· Forrás
Toboroz
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma
2023-506206-38-00· 2. fázis· Fondazione Italiana Linfomi Ets· Forrás
Toboroz
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· 3. fázis· AstraZeneca· Forrás
Toboroz
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793· 2. fázis· AstraZeneca· Forrás
Toboroz
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607· 2. fázis· AstraZeneca· Forrás
Toboroz
A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD)
2024-513019-29-00· 3. fázis· Mylan Inc.· Forrás
Toboroz
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma
2023-503288-40-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled, clinical trial, on the efficacy and tolerability of different escalating doses of intra-articular clodronate in patients with painful knee osteoarthritis
NCT06263517· 2/3. fázis· Spa Societa Prodotti Antibiotici S.p.A.· Forrás
Toboroz
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
NCT06918912· 2. fázis· Istituto Clinico Humanitas· Forrás
Toboroz
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139· 1/2. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
NCT05300282· 1/2. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Fut, nem toboroz
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
NCT05058404· 3. fázis· Fondazione Italiana Linfomi - ETS· Forrás
Fut, nem toboroz
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Post–Essential Thrombocythemia MF (Post-ET-MF) Who Have a Suboptimal Response to Ruxolitinib
2024-514468-26-00· 1/2. fázis· Kartos Therapeutics Inc.· Forrás
Toboroz
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198· 1/2. fázis· Sumitomo Pharma America, Inc.· Forrás
Fut, nem toboroz
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
NCT03610438· 2. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)
NCT03662126· 2/3. fázis· Kartos Therapeutics Inc.· Forrás
Fut, nem toboroz
MILES5 – A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC
NCT03975114· 2. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás